IRIS
MAFFIOLI, PAMELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.673
EU - Europa 3.928
AS - Asia 3.293
SA - Sud America 16
AF - Africa 14
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.584
CN - Cina 3.122
IE - Irlanda 1.173
UA - Ucraina 918
FI - Finlandia 600
DE - Germania 530
SE - Svezia 252
IT - Italia 218
GB - Regno Unito 138
SG - Singapore 95
CA - Canada 76
FR - Francia 23
RU - Federazione Russa 23
IN - India 22
IR - Iran 16
NL - Olanda 15
MX - Messico 11
ES - Italia 10
MU - Mauritius 9
TR - Turchia 8
PE - Perù 7
JO - Giordania 6
NZ - Nuova Zelanda 6
CO - Colombia 5
DZ - Algeria 5
JP - Giappone 5
MY - Malesia 5
BE - Belgio 4
RO - Romania 4
AU - Australia 3
BR - Brasile 3
GR - Grecia 3
HU - Ungheria 3
PK - Pakistan 3
PL - Polonia 3
AT - Austria 2
EE - Estonia 2
EU - Europa 2
LV - Lettonia 2
TH - Thailandia 2
UZ - Uzbekistan 2
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
CY - Cipro 1
DO - Repubblica Dominicana 1
IQ - Iraq 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MK - Macedonia 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
VE - Venezuela 1
Totale 12.935
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.326
Dublin 1.173
Chandler 1.053
Nanjing 999
Boardman 431
Nanchang 421
Ashburn 324
Shenyang 296
Hebei 283
Princeton 283
Lawrence 275
Medford 267
Wilmington 253
Changsha 248
Jiaxing 218
Hangzhou 170
Tianjin 144
Helsinki 117
Beijing 109
Toronto 67
Cambridge 54
Ann Arbor 53
Singapore 53
Woodbridge 49
Shanghai 45
Seattle 44
Milan 35
Fairfield 33
Norwalk 33
Des Moines 23
Jinan 23
Kunming 21
Bruino 19
Pavia 19
Los Angeles 18
Genova 17
Zhengzhou 16
Pune 14
Orange 13
Piscataway 13
New York 12
Ningbo 12
Guangzhou 11
Eindhoven 9
West Jordan 8
Fuzhou 7
Lima 7
Redwood City 7
Taizhou 7
Washington 7
Amman 6
Lanzhou 6
Leawood 6
Berlin 5
Bogotá 5
Changchun 5
Dallas 5
Dearborn 5
Houston 5
Moscow 5
Paris 5
Redmond 5
San Francisco 5
Shah Alam 5
Alcobendas 4
Auckland 4
Buffalo 4
Cagliari 4
Genoa 4
Halifax 4
Isernia 4
Kochi 4
Rotterdam 4
Shabestar 4
Tokyo 4
Verona 4
Bologna 3
Carpenedolo 3
Catania 3
Falkenstein 3
Mississauga 3
Novokuznetsk 3
Rome 3
St Petersburg 3
Tappahannock 3
Varanasi 3
Bangkok 2
Borås 2
Brisbane 2
Bruchsal 2
Brussels 2
Budapest 2
Cancún 2
Chicago 2
Crotone 2
Edmond 2
Falls Church 2
Frankfurt am Main 2
Grandate 2
Haikou 2
Totale 9.318
Salva come PNG Salva come JPEG
Nome #
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial 148
A randomized, placebo-controlled study about the effect of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters 123
Diagnostico y Tratamiento de los desordenes lipidicos. Mc Graw Hill Education 2014. 95
Effects of berberis aristata/silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients 79
Diarrea in paziente diabetico 77
Differential effect of candesartan and olmesartan on adipose tissue activity biomarkers in type 2 diabetic hypertensive patients 76
Comparison between exenatide and glimepiride on metabolic control and on insulin resistance in type 2 diabetic patients with metformin therapy 75
A possible way to improve the glycemic control and the beta cell function during three years: the triple therapy. 75
A multicenter, randomised, single-blind study on the effects of exenatide or glimepiride on insulin resistance. 72
Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study 69
Alkaloids in the nature: pharmacological applications in clinical practice of berberine and mate tea. 69
Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients 66
Different actions of losartan and ramipril on adipose tissue Activity and vascular remodeling biomarkers in hypertensive patients 66
n-3 PUFAs on metalloproteinases, inflammatory and insulin resistance parameters in dyslipidemic patients after euglycemic clamp and oral fat load. 66
Effects of berberine on lipid profile in subjects with low cardiovascular risk 66
Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. 66
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis 66
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation. 65
Aerobic physical activity in obese subjects compared to anaerobic/aerobic physical activity 65
A comparison between sitagliptin or glibenclamide in addition to metformin+pioglitazone on glycemic control and beta-cell function: the triple oral therapy 65
Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load 64
Canrenone on cardiovascular mortality in congestive heart failure: CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study 63
Effects of sibutramine plus L-carnitine compared to sibutramine on inflammatory parameters in type 2 diabetic patients 63
Vildagliptin added to metformin on β-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. 63
Effect of manidipine-rosuvastatin combination on fibrinolysis, inflammation markers and insulin sensitivity in hypertensive hypercholesterolemic patients 63
Acarbose compared to placebo on insulin resistance biomarkers in a double-blind, placebo-controlled trial 62
Berberis aristata/silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients 62
Berberis aristata/Silybum marianum fixed combination (Berberol®) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: A randomized, placebo-controlled, clinical trial. 62
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus 61
Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 61
Prevalence of erectile dysfunction in males affected by type 2 diabetes and the impact of hyperinsulinemia 61
Adipocytokines levels in obese and non-obese subjects, an observational study 61
Olmesartan/amlodipine combination vs olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients 61
Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin 60
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia during omega-3 polyunsaturated fatty acids therapy 60
Differenti effetti di candesartan e olmesartan sui parametri di attività del tessuto adiposo in pazienti diabetici di tipo 2 ipertesi 60
Metformina in bustine rispetto a metformina nella classica formulazione in compresse: primi risultati di uno studio clinico 60
Hypoglycemia, its implications in the clinical practice, and possible ways to prevent it. 60
Prevalence and associations of erectile dysfunction in a sample of italian males with type 2 diabetes. 60
Confronto tra candesartan e olmesartan sui parametri correlati alla sensibilità insulinica nei pazienti ipertesi con diabete mellito di tipo 2 60
A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients 59
Anti-obesity drugs: a review about their effects and their safety 59
Effetti di un carico lipidico orale sui marcatori di infiammazione e stress endoteliale nei soggetti sani 59
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients 58
Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients 58
Effetti di un carico lipidico orale sui marcatori di rimodellamento vascolare nei soggetti sani 58
Valutazione dei livelli di metalloproteasi 2 e 9 e dei loro inibitori nei soggetti con dislipidemia combinata 58
Effetto del telmisartan sui marcatori infiammatori a digiuno e postprandiale nei pazienti diabetici ipertesi 58
Rosiglitazone maleate and glimepiride in fixed combination for the metabolic control of type 2 diabetes 58
Sitagliptin in aggiunta alla precedente terapia ipoglicemizzante sull'insulino-resistenza e il profilo lipidico: uno studio a due anni 58
Valutazione dell’infiammazione e delle MMPs nei soggetti con e senza diabete durante OGTT 58
Pharmacotherapy for Obesity 58
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone 57
Matrix metalloproteinase-2 and – 9 levels in obese patients 57
Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients 57
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 57
Impact of the glyco-metabolic control on erectile dysfunction in patients with type 2 diabetes mellitus 57
Safety and efficacy of albiglutide-results from two trials 57
Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus 57
Candesartan effect on inflammation in hypertension 56
Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia 56
Pioglitazone paragonato a glibenclamide sul profilo lipidico e i parametri infiammatori nei pazienti diabetici di tipo 2 in terapia con metformina durante un carico orale di grassi 56
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients 56
Caso clinico: efficacia e sicurezza di exenatide LAR in un paziente diabetico obeso tipo 2. 56
Metformin powder formulation compared to metformin tablets on glycemic control and on treatment satisfaction in subjects with type 2 diabetes mellitus. 56
A randomized, double blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β-cell function. 56
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial 56
Effects of thiazolidinediones and sulfonylureas in patients with diabetes 55
Evaluation of candesartan compared to olmesartan on insulin sensitivity-related parameters in type 2 diabetic hypertensive patients 55
Glycemic excursions and variations of some inflammatory indices in patients with end-stage renal disease with and without type 2 diabetes mellitus undergoing two different dialysis techniques 55
Effetti della combinazione Berberis aristata/Silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti con basso rischio cardiovascolare 55
Effects of exenatide + metformin combination on some adipocytokines levels: a comparison with metformin monotherapy 55
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria 55
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. 55
A systematic reviewandmeta-analysis of randomized controlled trials investigating the effects of supplementationwith Nigella sativa (black seed) on blood pressure 55
Effetti sulla variabilità glicemica e sul compenso glico-metabolico di metformina, pioglitazone e sitagliptin in pazienti affetti da diabete mellito di tipo 2 55
Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study 55
Evaluation of candesartan compared to olmesartan on insulin-sensitivity related parameters in type 2 diabetic hypertensive patients 54
Effetti di un anno di trattamento con exenatide paragonato a glibenclamide in pazienti diabetici di tipo 2 54
Valutazione endocrino-metabolica di una popolazione di pazienti obesi e confronto con soggetti normopeso 54
The effects of different dialysis treatments on glycemic excursions and inflammation in patients with end-stage renal disease with and without type 2 diabetes mellitus 54
Effects of an olmesartan/amlodipine combination compared to olmesartan or amlodipine monotherapies on some insulin resistance parameters in hypertensive patients 54
Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin 54
Effetti di sitagliptin o metformina associati a pioglitazone in pazienti diabetici scarsamente controllati 54
Effects of sibutramine plus L-carnitine compared to sibutramine or placebo on inflammatory parameters 54
Effetti di una combinazione di un estratto di berberis aristata/silybum marianum sul profilo lipidico e la secrezione insulinica in pazienti dislipidemici 54
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients 53
Effect of aliskiren addition to losartan on fibrinolysis in diabetic hypertensive patients: a three-way crossover study. 53
Effetti di un anno di trattamento con orlistat+L-carnitina paragonato a orlistat o placebo sui parametri di insulino-resistenza nei pazienti diabetici 53
Prevalenza e fattori di rischio per la disfunzione erettile nei pazienti con diabete mellito di tipo 2 53
Current and emerging pharmacotherapies for the management of hypertension, focus on aliskiren 53
L'importanza di rimettere in discussione una diagnosi già fatta 53
Effects of irbesartan alone or in combination therapy 53
Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients 53
Effetti della formulazione idrosolubile di metformina sul compenso glicemico e sulla qualità della vita in pazienti con diabete mellito di tipo 2 53
Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study 52
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients 52
Comparative effect of amlodipine and amlodipine plus aliskiren on insulin sensitivity and inflammatory parameters in the treatment of hypertension in patients with metabolic syndrome 52
Effetti di un anno di trattamento con vildagliptin associato a pioglitazone o glimepiride in pazienti diabetici scarsamente controllati 52
Sitagliptin added to previously taken anti-diabetic agents on insulin resistance and lipid profile: a two years study evaluation 52
Totale 6.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.083
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.083
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020930 0 0 0 172 1 202 21 188 3 300 43 0
2020/20211.754 221 170 39 176 2 217 8 319 46 286 225 45
2021/20221.031 9 4 65 9 4 6 8 58 59 7 175 627
2022/20233.251 358 193 6 221 372 348 2 198 1.370 40 95 48
2023/20241.066 120 196 38 74 122 260 18 120 9 33 37 39
2024/2025480 25 331 98 26 0 0 0 0 0 0 0 0
Totale 13.275